An observational study in Fibromyalgia (FM), Pain and Catastrophizing Pain, sponsored by Faculdade de Ciências Médicas de Minas Gerais. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-19.
Sponsored by Faculdade de Ciências Médicas de Minas Gerais · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Fibromyalgia with a site in Brazil — 6 open to participants now, 8 under way, none of them phase 3. Fibromyalgia · Brazil.
Among the 60 studies in Fibromyalgia with a site in Brazil, this one is one of 5 that started in 2025, is one of 2 observational ones, and was the 55th registered.
1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →6 of the 60 studies in Fibromyalgia with a site in Brazil are open now. Recruiting first, the newest first:
Hospital de Clinicas de Porto Alegre · Sites in Brazil
Ages 18–75 · Women only
Federal University of the Valleys of Jequitinhonha and Mucuri · Sites in Brazil
Ages 18+ · Women only
Universidade Federal do Rio Grande do Norte · Sites in Brazil
Ages 18–65 · Women only
Universidade Federal do Triangulo Mineiro · Sites in Brazil
Ages 18–59 · Women only
Associação Pan-Americana Multidisciplinar de Endocanabinologia · Sites in Brazil
Ages 45–80 · Women only
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 5 · Phase 4 2
First in 2000; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 122 is above the median of 100 across 280 observational studies indexed under Fibromyalgia.
Median enrollment 60 across the 58 interventional studies, 72 across the 2 observational. Of the 33 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 60 have an industry lead sponsor. The 10 most frequent:
Faculdade de Ciências Médicas de Minas Gerais is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Faculdade de Ciências Médicas de Minas Gerais has 1 study filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
2 of the studies in Fibromyalgia with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07821034Federal University of the Valleys of Jequitinhonha and MucuriEffects of Reiki Therapy in Women With Fibromyalgia | 2026-12-15 |
| NCT07783295Associação Pan-Americana Multidisciplinar de EndocanabinologiaFull-Spectrum Cannabis Extract for Chronic Pain and Bone Health Biomarkers in Women | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 60 studies in Fibromyalgia with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Fibromyalgia (FM) is a chronic musculoskeletal pain syndrome with characteristics of generalized body pain, low pain threshold, tenderness and stiffness in muscles, tendons and joints. The assessment of pain in this condition is a challenge due to its subjective nature. A promising approach to assessing pain intensity is facial expression analysis, which can serve as an objective indicator. In addition, research seeks to identify molecular molecular markers to quantify pain. However, the lack of a standardized system has made it difficult to identify reliable markers. In summary, the search for objective methods of assessing pain in fibromyalgia is essential in order to develop more effective more effective treatments. Facial expression analysis and the investigation of molecular markers are promising ways of quantifying pain intensity more accurately and intensity of pain more accurately and reliably in fibromyalgia.
Introduction:
Fibromyalgia (FM) is a chronic syndrome characterized by diffuse musculoskeletal pain, fatigue and sleep disturbances, with a major impact on quality of life. Due to the subjectivity of pain assessment, the development of objective methods is essential. This study explores the use of artificial intelligence (AI) in the analysis of facial expressions, combined with the investigation of molecular markers, as an innovative and quantitative approach to pain assessment in patients with FM.
Objective:
To validate the application of an AI tool combined with facial expression analysis and molecular biomarker research to measure pain intensity in FM patients.
Methodology:
An observational cohort study was carried out with 122 participants, divided into two groups: patients with FM (n=61) and without FM (n=61). Data collection included:
The AI algorithm will use consistent facial patterns correlating them to the reported pain intensity, in agreement (Kappa=0.82) with the results of the clinical scales.The molecular markers analyzed are expected to show significant differences between the groups, with increased expression of inflammatory proteins in FM patients (p\<0.05). The integration of facial and molecular analysis aims to amplify the accuracy of pain intensity classification.
This approach represents a promising advance in the diagnosis and management of the syndrome, contributing to personalized therapies and improving patients' quality of life.
The study will be carried out with adult patients aged between 18 and 65 diagnosed with fibromyalgia at the outpatient clinic of the Faculdade Ciências Médicas de Minas Gerais and Clínica Ampla de Reumatologia in Belo Horizonte. The inclusion criteria were patients with no diagnosed cognitive deficit and who were willing to take part in the study. The exclusion criteria are patients who use medication that can affect anxiety or depression or who are unable to understand the instructions. Thus, once the patients agree to participate, they will be asked to sign the Informed Consent Form (ICF), which will provide detailed information about the nature of the study, the criteria for participation, the possible risks and benefits involved.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The aim is to follow fibromyalgia patients over a period of months to analyze pain intensity and identify molecular markers associated with the condition. The study encompasses facial analysis techniques and molecular markers, along with artificial intelligence tools, to quantify pain and understand the underlying mechanisms of fibromyalgia. The methodology is predominantly quantitative, focused on collecting and analyzing objective data on pain and associated markers.
The aim is to follow patients with pain over a period of months to analyze the intensity and identify molecular markers associated with the condition. The study encompasses facial analysis techniques and molecular markers, along with artificial intelligence tools, to quantify pain and understand the underlying mechanisms of fibromyalgia. The methodology is predominantly quantitative, focused on collecting and analyzing objective data on pain and associated markers.
Use the artificial intelligence tool to analyze the facial expression of patients with fibromyalgia in order to recognize pain.
Use the artificial intelligence tool to analyze the facial expression of patients with fibromyalgia in order to recognize pain. 61 patients with fibromyalgia will be compared with 61 patients without fibromyalgia.
Time frame: The estimated time for the anamnesis is one hour, during which time biological samples will be taken and each patient's facial expressions will be recorded on camera.
Biochemical analysis of biomarkers in the detection of pain in fibromyalgia.
122 samples containing 1ml of saliva will be collected in order to check for changes in oxidative stress and nociceptive markers (by spectrophotometry and ELISA).
Time frame: Estimated collection and analysis time: 5 hours of durability
Plan to share: Undecided
Started Nov 2025 (actual). Primary completion is estimated for Feb 2026, 2 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Faculdade de Ciências Médicas de Minas Gerais